IVD registration in Malaysia runs on its own rulebook.

What counts as an IVD medical device.

MDA's IVD classification guidance, MDA/GD/0001, defines an IVD medical device as any reagent, reagent product, calibrator, control material, kit, instrument, apparatus, equipment or system intended by its manufacturer for the in-vitro examination of specimens from the human body — including blood and tissue donations — to give information about a physiological or pathological state or congenital abnormality, about the safety and compatibility of a donation with a recipient, or to monitor therapy. Specimen receptacles are included.

That covers laboratory reagents and analysers, rapid tests used at the bedside, and self-test kits sold to the public. It does not cover a product for general laboratory use that is not made, sold or represented for a specified in-vitro diagnostic application — the ASEAN Medical Device Directive says in terms that such products are not IVD medical devices.

The legal obligation is the same as for every other device: under section 5(1) of the Medical Device Act 2012 (Act 737), no medical device may be imported, exported or placed on the market unless it is registered. What changes for IVDs is almost everything underneath — the classification rules, the CSDT guidance (MDA/GD/0004), the grouping categories (MDA/GD/0054), and even the contact: MDA lists a separate IVD registration inbox on its registration page. A team that has registered general devices before should not assume the same playbook carries over.

Seven rules, four classes, and the highest class wins.

Malaysia's IVD classification rules sit in the First Schedule of the Medical Device Regulations 2012, aligned with Annex 3 of the ASEAN Medical Device Directive, which is a separate rule set from the sixteen general-device rules in Annex 2. MDA explains the IVD rules in MDA/GD/0001, Second Edition (December 2020), and the harmonised ASEAN class list in MDA/GD/0062, Third Edition (June 2025) carries IVD entries too — over-the-counter blood glucose test systems as Class C, for instance.

Four questions drive every IVD class decision:

• Intended use — the analyte, the disease or condition, the population, and whether the test screens, diagnoses, aids diagnosis or monitors.
• Intended user — a lay person, a healthcare professional near the patient, or a laboratory.
• Weight of the result — is it the sole determinant of a diagnosis, or one of several?
• Impact of a wrong result — on the individual, and on public health.

Two tie-breakers matter in practice. If a device has several intended uses that land in different classes, it takes the higher class. If more than one rule applies, it takes the highest — MDA's own example is an HIV self-test, which is Class D under Rule 1, not Class C under Rule 4. And everything tied to a specific assay — its calibrators, controls, buffers, software and dedicated instrument — takes the class of that assay.

Examples are illustrations only — MDA/GD/0001 requires the rules to be applied to each device according to its own intended use. Where an establishment and a CAB disagree on a class, MDA's IVD classification summary says the establishment may ask MDA in writing within thirty days of the dispute, and MDA's decision is final. The general-device side is covered in the classification guide.

One analyser, one assay menu, four classes.

A distributor brings in an immunoassay platform with a starter menu. This is a hypothetical portfolio built to show the rules at work, not a client case:

There are two ways to file this. MDA's note on registering IVD analysers allows the analyser to be registered alone as Class A, with each reagent registered in its own right. Alternatively, analyser and reagents can be filed together as a system, where the analyser follows its reagents and MDA/GD/0054 lets you file one application per risk class — here a Class D application (HBsAg and anti-HCV with the analyser), a Class C and a Class B. Which is cheaper depends on how many assays share a class and whether you will later add assays from the same menu, so it is a decision to make before the dossier is built, not after.

Self-tests: a stricter rule and, for infectious disease, a policy gate.

Rule 4 puts a self-test in Class C unless its result is not medically critical, or is preliminary and needs a laboratory follow-up — then it is Class B. The reason MDA gives is simple: lay users have no technical expertise, so the labelling and instructions carry the whole outcome.

The setting written into the IFU matters as much as the analyte. In its published IVD Q&A, MDA considered a bench blood-gas analyser labelled for laboratory use only — not portable, not near-patient — and suggested Class B under Rule 6 rather than Class C under Rule 4.

The policy gate. The same Q&A states that registering an infectious-disease self-test needs a Ministry of Health policy first. MDA cited H. pylori antigen cassettes and urinary tract infection dipsticks as not allowed for self-testing, and noted no policy at the time for influenza or troponin I self-tests. For non-infectious self-tests, MDA said it had no specific restriction. Check the policy position before spending on a self-test dossier.

HIV self-tests have their own guidance, MDA/GD/0065 (Second Edition, January 2025). It classifies them as Class D; sets minimum sensitivity and specificity of 99.0% for blood specimens, and 92.0% sensitivity with 99.0% specificity for saliva; requires the IFU in English with a Bahasa Malaysia translation, QR codes to a video guide and to the TEST NOW platform (developed by the Malaysian AIDS Foundation with the Ministry of Health), a lay-suitable safety lancet for blood kits, and a disposal bag; and limits sale to the public to licensed community pharmacies, healthcare facilities and NGOs working with the Ministry — sale by individuals is prohibited. A kit without approval from a recognised country goes to full conformity assessment, with performance testing at the Institute for Medical Research (IMR) or an ISO 15189 accredited laboratory.

What goes into an IVD CSDT.

IVDs use the ASEAN Common Submission Dossier Template, but MDA's IVD version, MDA/GD/0004, asks for evidence a general-device dossier never touches. The headline requirements:

MDA/GD/0004 also requires every section to be present (with a reason where one does not apply), the dossier in English, reports signed off by the manufacturer, documents submitted in full, and certificates within their validity period.

Class A goes straight to MDA. Class B–D go through a CAB first.

MDA's IVD fee page states that Class A devices are exempt from conformity assessment under the Medical Device (Exemption) Order 2016. Class B, C and D IVDs need a registered Conformity Assessment Body before MDA will register them, by one of two routes:

• Verification, under MDA Circular Letter No. 2/2014 (Revision 5, effective 25 April 2022), where the IVD already holds a recognised approval. The IVD-specific list is narrower than it looks: notified-body certification under the old IVD Directive (Annex IV for List A; Annex IV or Annex V with Annex VII for List B and self-tests), CE certification under the EU IVD Regulation, or a EUDAMED listing. A self-declared Annex III IVD Directive declaration counts only for Class B. TGA, Health Canada, Japanese, US FDA (a 510(k) clearance or PMA letter) and UK MHRA approvals also qualify. The CAB checks that the intended use matches what the recognised authority approved.
• Full conformity assessment for everything else. Under MDA/GD/0003, the assessor must be satisfied that the manufacturer runs an appropriate quality system — a full one, including design and development, for Class C and D — and an adverse-event reporting procedure; the technical documentation review deepens with class, to an in-depth CSDT review for Class D; and the declaration of conformity is verified.

MDA's Singapore reliance route, in force since 1 March 2026, is announced for Class B–D devices on the Singapore Medical Device Register; the announcement does not single out IVDs, so we confirm eligibility product by product. See the Verification Route guide.

The business layer still applies. The registration has to be held by a licensed establishment — for a foreign manufacturer, a local authorized representative — and MDA/GD/0065 spells out for HIV self-tests that the manufacturer's ISO 13485 and the AR's, importer's and distributor's GDPMD certification must carry an IVD scope. Check the scope on your certificates before assuming an existing establishment licence covers a new diagnostics line.

IVD test kits and IVD clusters decide how many applications you file.

MDA/GD/0054 (Second Edition, January 2021) gives IVDs five grouping categories: single, system, family, IVD test kit and IVD cluster. The last two exist only for IVDs:

• IVD test kit — reagents or articles from one manufacturer, used together for one intended purpose, sold under one kit name and compatible as a kit. An HIV ELISA kit with its controls, calibrators and wash buffers is one application. Analysers are not part of a test kit.
• IVD cluster — reagents from one manufacturer, Class A or B only, sharing the same methodology, cluster category and test principle, taken from MDA's closed list of cluster categories. A cluster may include the analyser designed for its reagents. It cannot be used to add models later by change notification.

MDA's Q&A shows how literally the categories are applied: pregnancy kits that differ only in pack size are a family, not a test kit; reagents in different cluster categories cannot be combined; and an HIV self-test offered for whole blood, oral fluid and urine was told to split into separate applications by specimen type. Grouping is where a multi-product IVD budget is actually won or lost.

Where IVD registrations usually go wrong.

• Loose intended-use wording. “Screening” versus “aid to diagnosis”, “professional use” versus “self-test” — the intended use and intended user in the IFU set the rule, and the rule sets the class. MDA/GD/0004 asks for promotional material in the dossier too, so the brochure has to match the IFU.
• Assuming any CE mark earns verification. An IVD Directive self-declaration only supports verification for Class B. A Class C assay with nothing more goes to full conformity assessment unless another recognised approval or a EUDAMED listing applies.
• Registering one specimen type and adding the rest later. MDA treats a new sample type as a new registration, not a change notification.
• Thin stability data. Fewer than three lots, or accelerated data with no real-time programme behind it, falls short of what MDA/GD/0004 asks for.
• The wrong comparator. Method comparison is expected against an established device cleared by a reference agency, across every specimen type and anticoagulant the IFU permits.
• Registering the analyser and forgetting the reagents. A Class A analyser registration does not register the assays it runs.
• Building a self-test dossier before checking policy. For infectious-disease self-tests, MDA looks for a Ministry of Health policy first.

What IVD registration costs.

An IVD is priced like any other device: the class decides the fee, because the class decides whether a CAB is involved. Our fees are all-in — consultancy, CAB and MDA statutory fees in one number.

1000+ devices registered with MDA since 2016; registrations typically approved within 3 months, with MDA queries and resubmissions handled inside the quoted fee. Where kit or cluster grouping lets several reagents share one application, we quote the grouping case by case. Payment plans from RM1,500/month. Full schedule on pricing; the three cost layers are broken down in the cost guide.

MDA's own fees for IVDs are the standard Fifth Schedule figures: its IVD fee page lists the same application and registration fees as its general-device page, and MDA/GD/0065 quotes RM750 plus RM3,000 for a Class D HIV self-test. The table below is for reference only — it is already inside the fees above.

The order of work, and where the time goes.

1. Confirm the rule and the class against the IFU as written — and, for a self-test, the policy position.
2. Check the business layer — establishment licence held, and GDPMD or ISO 13485 scope covering IVDs.
3. Decide the grouping — test kit, cluster, system or single — and whether the analyser is filed alone or with its reagents.
4. Build the IVD CSDT. Stability needs the most lead time: accelerated data can support the initial shelf-life claim, but real-time studies must be under way, with the final report submitted when complete.
5. CAB conformity assessment for Class B–D, by verification or full assessment.
6. Submit through MeDC@St, answer MDA's queries, receive the registration.

Registrations we manage are typically approved within 3 months of submission. For HIV self-tests, MDA/GD/0065 states an evaluation period of 30 working days from submission of a complete application. For the general process, see how to register a medical device, or have us run it through our MDA registration service.